Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 9, 2012, Pages 1245-1253

  Adi, Handoko ^a   Young, Paul M ^a   Traini, Daniela ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

budesonide; chronic obstructive pulmonary disease; formoterol fumarate dihydrate; ipratropium bromide; triple therapy

Indexed keywords

ALCOHOL; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DEPOSITION; DRUG FORMULATION; IN VITRO STUDY; METERED DOSE INHALER; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; PRESSURISED METERED DOSE INHALER;

ADMINISTRATION, INHALATION; AEROSOLS; BRONCHODILATOR AGENTS; BUDESONIDE; CHEMISTRY, PHARMACEUTICAL; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; ETHANOL; ETHANOLAMINES; FEASIBILITY STUDIES; HUMANS; IPRATROPIUM; METERED DOSE INHALERS; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; PHARMACEUTICAL VEHICLES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SOLUBILITY; SOLUTIONS; SOLVENTS;

EID: 84864669889     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01370.x     Document Type: Article

References (51)

1. Smyth HD,. Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2005; 2: 53-74. (Pubitemid 40123883)
2. Newhouse M,. Advantages of pressurized canister metered dose inhalers. J Aerosol Med 1991; 4: 139-150.
3. Warren SJ, Farr SJ,. Formulation of solution metered-dose inhalers and comparison with aerosols emitted from conventional suspension systems. Int J Pharm 1995; 124: 195-203.
4. Smyth HDC,. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev 2003; 55: 807-828. (Pubitemid 36776795)
5. Pritchard JN,. The influence of lung deposition on clinical response. J Aerosol Med 2001; 14 (Suppl. 1): S19-S26. (Pubitemid 32172850)
6. Kirk WF,. In vitro method of comparing clouds produced from inhalation aerosols for efficiency in penetration of airways. J Pharm Sci 1972; 61: 262-265.
7. Dalby RN, et al,. Inhalation Aerosols Physical and Biological Basis for Therapy., Hickey AJ, ed. New York: Mercel Dekker Inc., 1996.
8. Gupta A, et al,. Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers. J Aerosol Med 2003; 16: 167-174. (Pubitemid 36702670)
9. Stein SW, Myrdal PB,. The relative influence of atomization and evaporation on metered dose inhaler drug delivery efficiency. Aerosol Sci Technol 2006; 40: 335-347.
10. Berg E,. In vitro properties of pressurized metered dose inhalers with and without spacer devices. J Aerosol Med 1995; 8 (Suppl. 3): S3-10; discussion S11.
11. Polli GP, et al,. Influence of formulation on aerosol particle size. J Pharm Sci 1969; 58: 484-486.
12. Leach CL, et al,. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12: 1346-1353. (Pubitemid 29011427)
13. Lyseng-Willianison KA, Simpson D,. Budesonide/formoterol pressurized metered-dose inhaler. Drugs 2008; 68: 1855-1864.
14. Goldsmith DR, Keating GM,. Budesonide/formoterol-a review of its use in asthma. Drugs 2004; 64: 1597-1618. (Pubitemid 38981841)
15. Salama RO, et al,. Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease? Expert Opin Pharmacother 2011; 12: 1913-1932.
16. Tal A, et al,. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002; 34: 342-350. (Pubitemid 35192788)
17. Bateman ED, et al,. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med 2003; 2: 275-281. (Pubitemid 36869441)
18. Qaseem A, et al,. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 147: 633-638. (Pubitemid 351664484)
19. Chapman KR, et al,. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999; 6: 45-51. (Pubitemid 29158748)
20. Nelson HS, et al,. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003; 112: 29-36. (Pubitemid 36819803)
21. Zetterstrom O, et al,. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18: 262-268. (Pubitemid 32776399)
22. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest 1997; 112: 1514-1521.
23. FitzGerald JM, et al,. The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group. Chest 1997; 111: 311-315.
24. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105: 1411-1419.
25. Postma DS, et al,. Influence of the parasympathetic and sympathetic nervous system on nocturnal bronchial obstruction. Clin Sci (Lond) 1985; 69: 251-258. (Pubitemid 15246104)
26. Pakes GE, et al,. Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs 1980; 20: 237-266. (Pubitemid 11191899)
27. Koumis T, Samuel S,. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 2005; 27: 377-392. (Pubitemid 40732646)
28. Bateman ED, et al,. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther 2009; 22: 533-542.
29. Karpel JP, et al,. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD. Chest 1994; 105: 1089-1094. (Pubitemid 24112795)
30. Welte T, et al,. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-750.
31. Niewoehner DE, et al,. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2009; 22: 587-592.
32. Tashkin DP, et al,. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med 1996; 100: 62S-669.
33. D'Urzo AD, et al,. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001; 119: 1347-1356. (Pubitemid 32686014)
34. van Noord JA, et al,. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878-885. (Pubitemid 30321844)
35. Rabe KF, et al,. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134: 255-262.
36. Cazzola M, et al,. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007; 20: 556-561. (Pubitemid 47077647)
37. Johnson M,. Corticosteroids: potential beta2-agonist and anticholinergic interactions in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 320-325; discussion 340-1. (Pubitemid 41566943)
38. Perng DW, et al,. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology 2006; 11: 598-602.
39. Singh D, et al,. Superiority of 'triple' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592-598. (Pubitemid 351969251)
40. Aaron SD, et al,. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555. (Pubitemid 351650535)
41. Lee TA, et al,. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009; 169: 1403-1410.
42. Formulated Preparations: General Monographs, Preparations for inhalation. British Pharmacopoeia. Norwich, UK: TSO (The Stationery Office), 2010: 3.
43. Atrovent Consumer Medicine Information. Atrovent Inhalation Solution. 2006 [cited 13 May 2011]; Available from: http://www.racgp.org.au/cmi/bycatrso. pdf.
44. Brambilla G, et al,. Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int J Pharm 1999; 186: 53-61. (Pubitemid 29397522)
45. Smyth HD,. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev 2003; 55: 807-828. (Pubitemid 36776795)
46. AstraZeneca. Symbicort 80/4.5 and Symbicort 160/4.5. 2010 [Prescribing Information Leaflet][cited 29 March 2011]; Available from: http://www1. astrazeneca-us.com/pi/symbicort.pdf.
47. Traini D, et al,. Surface energy and interparticle forces correlations in model pMDI formulations. Pharm Res 2005; 22: 816-825. (Pubitemid 40768595)
48. Huchon G, et al,. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009; 103: 41-49.
49. Theophilus A, et al,. Co-deposition of salmeterol and fluticasone propionate by a combination inhaler. Int J Pharm 2006; 313: 14-22.
50. Myerson A,. Handbook of Industrial Crystallization, 2nd edn., Myerson AS,. Maryland Heights, MO: Elsevier Inc, 2002.
51. Rogueda PG, et al,. Particle synergy and aerosol performance in non-aqueous liquid of two combinations metered dose inhalation formulations: an AFM and Raman investigation. J Colloid Interface Sci 2011; 361: 649-655.